Table 3 Immunohistochemical results of published CIRC tumors
Author(s) | Primary/Relapse | CAM5.2 (CK8) | CK18 | AE1/AE3 | EMA | Vimentin | Desmin | α-SMA | S-100 | CD21 | CD68 | p53 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gould et al. [8] | + | + | + | + | + | – | + | – | ND | ND | ND | |
Gould et al. [8] | + | + | + | + | + | + | + | – | ND | ND | ND | |
Gould et al. [8] | + | + | + | – | + | + | + | – | ND | ND | ND | |
Chan et al. [9] | + | + | + | +/− | + | – | – | – | – | – | ND | |
Chan et al. [9] | + | + | – | – | + | + | + | – | – | – | ND | |
Chan et al. [9] | + | + | + | +/− | + | – | – | – | – | – | ND | |
Schuerfeld et al. [10] | + | + | + | – | + | + | ND | + | – | + | ND | |
Lucioni et al. [11] | *primary | – | ND | – | – | + | – | + | – | – | + | 20% |
relapse | + | ND | +/− | – | + | – | – | – | – | – | > 60% | |
Karim et al. [12] | ND | ND | + | ND | ND | + | + | – | – | ND | ND | |
Goto et al. [13] | + | ND | + | +/− | ND | – | – | +/− | +/− | – | ND | |
Bösmüller et al. [14] | + | ND | + | – | + | – | – | – | – | + | +/− | |
Current case | primary | + | + | + | + | + | – | – | – | – | – | 95% |
relapse | + | + | + | + | + | – | – | – | – | – | 80% |